«ОЦЕНКА ПАРАМЕТРОВ ЦЕНТРАЛЬНОЙ ГЕМОДИНАМИКИ У ПАЦИЕНТОВ С НЕЙРОИШЕМИЧЕСКОЙ ФОРМОЙ СИНДРОМА ДИАБЕТИЧЕСКОЙ СТОПЫ АССОЦИИРОВАННО С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА»
##article.subject##:
diabetik tupiq sindromi, koronar yurak kasalligi, markaziy gemodinamika##article.abstract##
Tadqiqotning maqsadi - yurakning ultratovushli dogplerografiyasi natijalarini, yostiq yurak kasalligi bilan bog'liq diabetik tupiq sindromi (DTS) bo'lgan neyretik oyoq sindromi bo'lgan bemorlarda.
Material va tadqiqot usullari. 2021-2022 yillarda 2021-2022 yillarda biz nevrohemik shaklda bo'lgan 70 nafar bemorlar tomonidan tekshirilgan. Bemorlar 4 guruhga tarqatildi:
1 g - 2 turdagi diabet va YIK - 21 ta bemorlarning diabet va neyroishemik shakli bo'lgan bemorlar,
2-guruh - yurak ishemik kasalligi (YIK)bo'lmagan diabet va neyryichemik shakli bo'lgan bemorlar - 18 ta bemorlar,
2 tipidagi diabet va neyryichemik shakli bo'lgan 3-guruh, YIK va discirkulator ensefalopatiya 2-3 osh qoshiq ensefalopatiyasi 2-3 osh qoshiq ensefalopatiya.
4-guruh - uglevod metabolizmini buzmasdan - 15 bemor.
Sog'lom ko'ngillilar (n = 20) boshqaruv guruhini tuzdilar.
4-guruhning barcha bemorlari asosiy guruhni tashkil etishdi. Ularning barchasi umumiy klinik, biokimyoviy (glycemia, glyoglej, galirubin, biiqyubin, karbamid, karbamid, karbamid, karbamid), gormonal (IRI, C-Spepide va boshqalar) va tadqiqot - tadqiqot - tadqiqot - tadqiqotning dopplerografiyografiyasini aks ettirgan Miyaning tomirlari, pastki oyoq tomlari, kichik oyoq-qo'llar, ekz, echo-ekg, yarasidan ajratilgan va statistik usullar.
Natijalar. KDO LV KDOG DTS va YIK (107.1 ± 5.221 *) bilan og'rigan bemorlarda boshqaruv guruhiga qaraganda ancha past bo'lgan (120,5 ± 2,57ml; p <0.05). Bemorlarda LV ning o'rtacha TIMI Groccontrol-ga qaraganda ancha past (52,5 ± 1.33 mln. P <0.05) ga qaraganda ancha past (34.04 ± 2.61 *). KDO va CSSE LV tomonidan ishlab chiqarilgan, SDS va IBS bilan og'rigan bemorlarda boshqaruv guruhi (p <0.05) ma'lumotlariga nisbatan statistik jihatdan muhim farqlarga ega bo'ldi.
Xulosa. 1. Xemodinamikaning ekmosanamikadagi o'zgarishlar surunkali yurak etishmovchiligi klinikasi paydo bo'lishidan oldin kuzatiladi. 2. EchcoCG o'zgarishi 1-guruhning 1 tipidagi DTS va YIKning 2 turi va neyreymic shakli bo'lgan bemorlarda talaffuz qilinadi.
Библиографические ссылки
Jean-Louis Schlienger 1 [Type 2 diabetes complications] Presse Med. 2013 May;42(5):839-48. Doi: 10.1016/j.lpm.2013.02.313. Epub 2013 Mar 23.
Isa Dietrich 1 2, Gustavo Arruda Braga 3, Fernanda Gomes de Melo 3, Ana Carolina Calmon da Costa Silva Silva 3The Diabetic Foot as a Proxy for Cardiovascular Events and Mortality Review Curr Atheroscler Rep. 2017 Oct 2;19(11):44. Doi: 10.1007/s11883-017-0680-z.
Barbara Bohn 1 2, Arthur Grünerbel 3, Marcus Altmeier 4, Carsten Giesche 5, Martin Pfeifer 6, Diabetic foot syndrome in patients with diabetes. A multicenter German/Austrian DPV analysis on 33 870 patients //Diabetes Metab Res Rev. 2018 Sep;34(6):e3020.doi: 10.1002/dmrr.3020. Epub 2018 Jun 1.
Antonino Tuttolomondo,1 Carlo Maida,1 and Antonio Pinto1Diabetic Foot Syndrome as a Possible //Cardiovascular Marker in Diabetic Patients Ъreview Article | Open Access Volume 2015 |Article ID 268390 | https://doi.org/10.1155/2015/268390
American Diabetes Association, “Consensus development conference on diabetic foot wound care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association,” Diabetes Care, vol. 22, no. 8, pp. 1354–1360, 1999.View at:
R. E. Pecoraro, G. E. Reiber, and E. M. Burgess, “Pathways to diabetic limb amputation: basis for prevention,” Diabetes Care, vol. 13, no. 5, pp. 513–521, 1990.
M. P. Khanolkar, S. C. Bain, and J. W. Stephens, “The diabetic foot,” QJM, vol. 101, no. 9, pp. 685–695, 2008.
G. E. Reiber, “Epidemiology of foot ulcers and amputations in the diabetic foot,” in The Diabetic Foot, J. H. Bowker and M. A. Pfeifer, Eds., pp. 13–32, Mosby, St. Louis, Mo, USA, 2001.
S. E. Moss, R. Klein, and B. E. K. Klein, “The prevalence and incidence of lower extremity amputation in a diabetic population,” Archives of Internal Medicine, vol. 152, no. 3, pp. 610–616, 1992.
S. D. Ramsey, K. Newton, D. Blough et al., “Incidence, outcomes, and cost of foot ulcers in patients with diabetes,” Diabetes Care, vol. 22, no. 3, pp. 382–387, 1999.
C. A. Abbott, L. Vileikyte, S. Williamson, A. L. Carrington, and A. J. M. Boulton, “Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration,” Diabetes Care, vol. 21, no. 7, pp. 1071–1075, 1998.
D. P. Walters, W. Gatling, M. A. Mullee, and R. D. Hill, “The distribution and severity of diabetic foot disease: a community study with comparison to a non-diabetic group,” Diabetic Medicine, vol. 9, no. 4, pp. 354–358, 1992.View at:
P. LeQuesne, N. Parkshouse, and I. Faris, “Neuropathy,” in The Management of the Diabetic Foot, I. Faris, Ed., p. 41, Churchill Livingstone, Edinburgh, Scotland, 2nd edition, 1991.
G. E. Reiber, D. G. Smith, L. Vileikyte et al., “Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings,” Diabetes Care, vol. 22, no. 1, pp. 157–162, 1999.
R. D. Abbott, F. N. Brand, and W. B. Kannel, “Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study,” The American Journal of Medicine, vol. 88, no. 4, pp. 376–381, 1990.
C. Daousi, I. A. MacFarlane, A. Woodward, T. J. Nurmikkot, P. E. Bundred, and S. J. Benbow, “Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes,” Diabetic Medicine, vol. 21, no. 9, pp. 976–982, 2004.
A. Pinto, A. Tuttolomondo, D. Di Raimondo et al., “Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot,” Metabolism, vol. 57, no. 5, pp. 676–682, 2008.View at:
N. A. Roper, R. W. Bilous, W. F. Kelly, N. C. Unwin, and V. M. Connolly, “Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study,” British Medical Journal, vol. 322, no. 7299, pp. 1389–1393, 2001.
W. B. Kannel and D. L. McGee, “Diabetes and cardiovascular disease: the Framingham study,” The Journal of the American Medical Association, vol. 241, no. 19, pp. 2035–2038, 1979.
J. S. Rana, M. Nieuwdorp, J. W. Jukema, and J. J. P. Kastelein, “Cardiovascular metabolic syndrome—an interplay of, obesity, inflammation, diabetes and coronary heart disease,” Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 218–232, 2007.
A. Pinto, A. Tuttolomondo, D. di Raimondo et al., “Ischemic stroke in patients with diabetic foot,” International Angiology, vol. 26, no. 3, pp. 266–269, 2007.View at:
A. Tuttolomondo, S. La Placa, D. Di Raimondo et al., “Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity,” Cardiovascular Diabetology, vol. 9, article 50, 2010.
H. Sell and J. Eckel, “Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?” Proceedings of the Nutrition Society, vol. 68, no. 4, pp. 378–384, 2009.
J.-P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006.
